14-day Premium Trial Subscription Try For FreeTry Free
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting
Upgrades According to Oppenheimer, the prior rating for Apollo Global Management Inc (NYSE:APO) was changed from Perform to Outperform. In the fourth quarter, Apollo Global Management showed an EPS of
LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered dir
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA

Why Celsion Shares Are Pulling Back Today

09:39am, Wednesday, 06'th Apr 2022
Celsion Corp (NASDAQ: CLSN) shares are trading lower Wednesday after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules. What To Know: The offering
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA

Why Celsion Stock Is Surging Today

06:50pm, Tuesday, 05'th Apr 2022 Benzinga
Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock. Zacks analyst David Bautz highlighted the

Why Celsion Stock Is Surging Today

03:17pm, Tuesday, 05'th Apr 2022
Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock. Zacks analyst David Bautz highlighted the
Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, anno
A 1-for-15 reverse split of Celsion Corporation (NASDAQ: CLSN) stock has gone into effect. These are the details.
Celsion <> received $1.4M in net cash proceeds from the sale of ~$1.5M of its unused New Jersey net operating losses.Strengthening its balance sheet, this non-dilutive funding adds…
Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024

Celsion under pressure on 1-for-15 reverse stock split

01:52pm, Monday, 28'th Feb 2022 Seeking Alpha
Celsion (CLSN) trades 8.1% down premarket after it plans to implement a consolidation (reverse stock split) of its outstanding shares on the basis of 1-for-15 currently…

Celsion Corporation Announces Stock Consolidation

01:30pm, Monday, 28'th Feb 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE